Share ownership Arcus Biosciences, Inc.

RCUS

US03969F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:20:58 10/09/2024 BST			5-day change	1st Jan Change
16.24 ^USD	-0.46%		-2.35%	-15.29%

09-04	Transcript : Arcus Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM
08-27	Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital	MT

Share class: Arcus Biosciences, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	91,427,505	54,274,173 ( 59.36 %)	0	59.36 %

Major shareholders: Arcus Biosciences, Inc.

Name	Equities	%	Valuation
Gilead Sciences, Inc. 34.49 %	31,532,781	34.49 %	540 M $
BlackRock Advisors LLC 10.16 %	9,289,480	10.16 %	159 M $
Vanguard Fiduciary Trust Co. 5.750 %	5,257,326	5.750 %	90 M $
Woodline Partners LP 4.643 %	4,245,221	4.643 %	73 M $
Fidelity Management & Research Co. LLC 4.573 %	4,180,791	4.573 %	72 M $
Terry Rosen 4.325 %	3,954,304	4.325 %	68 M $
State Street Corp. 3.342 %	3,055,056	3.342 %	52 M $
Point72 Asset Management LP 2.006 %	1,833,851	2.006 %	31 M $
Invus Financial Advisors LLC 1.763 %	1,612,077	1.763 %	28 M $
Boxer Capital LLC 1.752 %	1,602,200	1.752 %	27 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	50.13%
Gilead Sciences, Inc.	34.49%
Individuals	7.76%
Other	3.78%
State Street Corp.	3.34%
Schweizerische Nationalbank	0.11%
Corebridge Financial, Inc.	0.03%
Manulife Financial Corp.	0.03%
Governments	0.03%
Unknown	0.30%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	85.87%
Individuals	7.76%
Australia	1.72%
United Kingdom	1.20%
China	0.95%
Ireland	0.49%
Canada	0.36%
Spain	0.30%
Denmark	0.25%
Switzerland	0.24%
Sweden	0.20%
Cayman Islands	0.10%
France	0.07%
Luxembourg	0.07%
Singapore	0.05%
Germany	0.02%
Norway	0.02%
Hong Kong	0.01%
Taiwan	0.01%
United Arab Emirates	0.01%

Based on 1000 largest holdings

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Employees

577

Sector

Biotechnology & Medical Research

Calendar

19/09/2024 - Cantor Global Healthcare Conference - Fireside Chat

Related indices

Russell 2000

More about the company